Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Depression in Adolescence: A Systematic Review.


Journal

Journal of affective disorders
ISSN: 1573-2517
Titre abrégé: J Affect Disord
Pays: Netherlands
ID NLM: 7906073

Informations de publication

Date de publication:
01 01 2021
Historique:
received: 21 07 2020
revised: 09 09 2020
accepted: 11 09 2020
pubmed: 5 10 2020
medline: 20 4 2021
entrez: 4 10 2020
Statut: ppublish

Résumé

There is evidence that repetitive transcranial magnetic stimulation (rTMS) is effective for treating adult depression. However, it remains unclear whether rTMS is an effective treatment for adolescent depression. This systematic review examines the existing literature on the effectiveness and acceptability of rTMS in the treatment of adolescent depression. After protocol registration (PROSPERO), we searched PubMed, Embase, PsycINFO, WoS and CENTRAL databases and the grey literature. We included studies that used rTMS in adolescents aged 12-25 years old who had a clinical diagnosis of depression. Study quality was assessed using the Newcastle-Ottawa Scale. Fourteen studies were identified, which included 8 open-trial studies (N = 142 participants) and six studies which performed further post-hoc/follow-up analyses on these open-trial datasets. All studies suffered from multiple biases but reported that rTMS treatment reduced depression scores in adolescents. A single study on theta burst stimulation also found a positive effect. No study to date includes a sham control. Reported side effects of rTMS included scalp pain, headache and dizziness. Study methodologies precluded a meta-analysis. The current literature signals that rTMS could reduce adolescent depressive symptoms. However, sham controlled randomized trials are needed. These findings suggest that rTMS may be a promising treatment option for adolescents with depression.

Sections du résumé

BACKGROUND
There is evidence that repetitive transcranial magnetic stimulation (rTMS) is effective for treating adult depression. However, it remains unclear whether rTMS is an effective treatment for adolescent depression. This systematic review examines the existing literature on the effectiveness and acceptability of rTMS in the treatment of adolescent depression.
METHODS
After protocol registration (PROSPERO), we searched PubMed, Embase, PsycINFO, WoS and CENTRAL databases and the grey literature. We included studies that used rTMS in adolescents aged 12-25 years old who had a clinical diagnosis of depression. Study quality was assessed using the Newcastle-Ottawa Scale.
RESULTS
Fourteen studies were identified, which included 8 open-trial studies (N = 142 participants) and six studies which performed further post-hoc/follow-up analyses on these open-trial datasets. All studies suffered from multiple biases but reported that rTMS treatment reduced depression scores in adolescents. A single study on theta burst stimulation also found a positive effect. No study to date includes a sham control. Reported side effects of rTMS included scalp pain, headache and dizziness.
LIMITATIONS
Study methodologies precluded a meta-analysis.
CONCLUSIONS
The current literature signals that rTMS could reduce adolescent depressive symptoms. However, sham controlled randomized trials are needed. These findings suggest that rTMS may be a promising treatment option for adolescents with depression.

Identifiants

pubmed: 33011525
pii: S0165-0327(20)32753-1
doi: 10.1016/j.jad.2020.09.058
pii:
doi:

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

460-469

Informations de copyright

Copyright © 2020. Published by Elsevier B.V.

Auteurs

Danielle Hett (D)

Institute for Mental Health, University of Birmingham, Edgbaston, Birmingham, B15 2TT, United Kingdom; National Centre for Mental Health, The Barberry, 25 Vincent Drive, Birmingham and Solihull Mental Health Trust, Birmingham, B15 2FG, United Kingdom. Electronic address: D.Hett@bham.ac.uk.

Jack Rogers (J)

Institute for Mental Health, University of Birmingham, Edgbaston, Birmingham, B15 2TT, United Kingdom.

Clara Humpston (C)

Institute for Mental Health, University of Birmingham, Edgbaston, Birmingham, B15 2TT, United Kingdom.

Steven Marwaha (S)

Institute for Mental Health, University of Birmingham, Edgbaston, Birmingham, B15 2TT, United Kingdom; National Centre for Mental Health, The Barberry, 25 Vincent Drive, Birmingham and Solihull Mental Health Trust, Birmingham, B15 2FG, United Kingdom; Specialist Mood Disorders Clinic, Zinnia Centre, Birmingham and Solihull Mental Health Trust, Birmingham, B11 4HL, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH